PDS Biotechnology Corporation is asking stockholders to vote on director elections, share authorization, auditor ratification, and executive pay at its 2026 virtual annual meeting. The meeting will be held online on August 10, 2026 at 8 a.m. Eastern Time, with access via a 16-digit control number.
Stockholders of record as of June 15, 2026, when 55,815,653 common shares were outstanding and entitled to vote, may participate. The proxy details board structure, committee memberships, independence, and executive biographies, and explains compensation, including base salaries, stock option grants, and severance terms for senior management and fees and equity awards for non-employee directors.
PDS Biotechnology Corporation filed a prospectus supplement to offer up to $50,000,000 of its common stock in an at-the-market offering under a Sales Agreement with Yorkville Securities and B. Riley Securities.
The supplement states the Agents will act as sales agents or principals and receive a 3.0% commission. The company recently closed a financing with YA II that included a $6,000,000 promissory note and a warrant to purchase 2,158,274 shares at an exercise price of $1.1824 per share. The company agreed to file a registration statement to register resale of shares issuable on conversion or exercise. The prospectus shows an illustrative post-offering outstanding share count of up to 103,434,701 shares based on specified assumptions.
PDS Biotechnology Corporation is soliciting proxies for its virtual Annual Meeting of Stockholders to be held on August 10, 2026. The Board asks shareholders to vote on the election of two directors, an amendment to increase authorized common shares, ratification of the independent auditor, and an advisory vote on executive compensation.
The record date for voting was June 15, 2026, when 55,815,653 shares of common stock were outstanding. The proxy materials and the 2025 Annual Report on Form 10-K are being made available beginning on or about June 26, 2026. Voting instructions and virtual meeting access details are included in the distributed materials.
PDS Biotechnology Corporation closed a financing with YA II PN, Ltd., issuing a $6,000,000 Promissory Note, sold for $5,760,000, and a Warrant to purchase 2,158,274 common shares at $1.1824 per share. The note matures 12 months after the June 15, 2026 closing and carries 10% annual interest.
The company also put in place a Sales Agreement for an “at-the-market” stock offering of up to $50,000,000 of common shares, paying a 3.0% commission on sales. On the closing date, it redeemed in full its prior Senior Secured Convertible Debentures at 103% of principal plus accrued interest, extinguishing related rights.
PDS Biotechnology Corporation has scheduled its 2026 Annual Meeting of Stockholders for August 10, 2026. The meeting date is more than 30 days after the anniversary of the 2025 Annual Meeting, so the company has set a special deadline for stockholder proposals.
Stockholders seeking to include proposals in the proxy materials under SEC Rule 14a-8 must submit them by June 25, 2026. Eligible proposals must comply with SEC rules and should be sent to the Corporate Secretary at the company’s Princeton, New Jersey headquarters.
PDS Biotechnology Corporation reported that it has regained compliance with the Nasdaq Capital Market’s minimum bid price rule. Nasdaq had previously notified the company that its common stock closed below the required $1.00 per share for 30 consecutive business days, triggering a deficiency notice. On June 2, 2026, Nasdaq informed PDS Biotechnology that the company once again meets the Minimum Bid Price Requirement and that the compliance matter is now closed.
PDS Biotechnology reported another quarterly loss as it continues to fund its cancer and infectious disease immunotherapy pipeline with no product revenue. For the three months ended March 31, 2026, net loss was $7.3 million, improving from $8.5 million a year earlier, mainly because research and development spending fell to $3.5 million from $5.8 million. General and administrative costs eased slightly to $3.1 million.
Cash and cash equivalents were $21.7 million at March 31, 2026, down from $40.0 million a year earlier, after using $4.4 million in operating cash during the quarter and making $1.5 million of principal payments on senior secured convertible debentures. Total assets were $24.7 million and stockholders’ equity declined to $3.9 million, with an accumulated deficit of $224.0 million.
The company reiterates that it has no revenues, expects ongoing operating losses, and faces restrictive covenants on its $22.2 million debentures, including minimum cash requirements. Management concludes that these conditions raise substantial doubt about its ability to continue as a going concern over the next 12 months. Subsequent to quarter-end, PDS agreed to issue a $6.0 million promissory note with attached warrants and plans to redeem all outstanding debentures for cash in June 2026, subject to closing conditions.
PDS Biotechnology reported first quarter 2026 results and a clinical pipeline update. Net loss was about $7.3 million, or $0.13 per share, improving from a loss of $8.5 million, or $0.21 per share, a year earlier.
Research and development expenses fell to $3.5 million from $5.8 million, mainly from lower clinical and manufacturing costs, while general and administrative expenses edged down to $3.1 million. Cash and cash equivalents were $21.7 million as of March 31, 2026, with long‑term debt of $10.6 million and stockholders’ equity of $3.9 million.
Management highlighted progress on the amended VERSATILE‑003 Phase 3 trial in HPV16‑positive head and neck cancer and ongoing Phase 2 studies of PDS01ADC in metastatic colorectal and advanced castration‑resistant prostate cancers.
PDS Biotechnology Corporation entered into a financing deal with YA II PN, LTD., agreeing to issue a $6,000,000 promissory note and a warrant for 2,158,274 common shares at an exercise price of $1.1824 per share. The note, sold for $5,760,000, carries 10% annual interest, matures 12 months after closing, and can become convertible at a discount to market prices if the company is late on payments, subject to ownership and Nasdaq 19.99% caps. PDS will also enter an at-the-market sales agreement with Yorkville Securities, LLC and has delivered notices to redeem its existing senior secured convertible debentures at 103% of principal plus interest on June 12, 2026, using cash.